XYOSTED (AUTOINJECTOR) Drug Patent Profile
✉ Email this page to a colleague
When do Xyosted (autoinjector) patents expire, and what generic alternatives are available?
Xyosted (autoinjector) is a drug marketed by Antares Pharma Inc and is included in one NDA. There are twenty-three patents protecting this drug.
This drug has ninety-seven patent family members in fourteen countries.
The generic ingredient in XYOSTED (AUTOINJECTOR) is testosterone enanthate. There are sixty-nine drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the testosterone enanthate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Xyosted (autoinjector)
A generic version of XYOSTED (AUTOINJECTOR) was approved as testosterone enanthate by NEXUS on June 14th, 2006.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for XYOSTED (AUTOINJECTOR)?
- What are the global sales for XYOSTED (AUTOINJECTOR)?
- What is Average Wholesale Price for XYOSTED (AUTOINJECTOR)?
Summary for XYOSTED (AUTOINJECTOR)
International Patents: | 97 |
US Patents: | 23 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 55 |
Patent Applications: | 2,630 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for XYOSTED (AUTOINJECTOR) |
DailyMed Link: | XYOSTED (AUTOINJECTOR) at DailyMed |
Pharmacology for XYOSTED (AUTOINJECTOR)
Drug Class | Androgen |
Mechanism of Action | Androgen Receptor Agonists |
US Patents and Regulatory Information for XYOSTED (AUTOINJECTOR)
XYOSTED (AUTOINJECTOR) is protected by twenty-three US patents.
Expired US Patents for XYOSTED (AUTOINJECTOR)
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Antares Pharma Inc | XYOSTED (AUTOINJECTOR) | testosterone enanthate | SOLUTION;SUBCUTANEOUS | 209863-002 | Sep 28, 2018 | RE44847 | ⤷ Subscribe |
Antares Pharma Inc | XYOSTED (AUTOINJECTOR) | testosterone enanthate | SOLUTION;SUBCUTANEOUS | 209863-003 | Sep 28, 2018 | RE44847 | ⤷ Subscribe |
Antares Pharma Inc | XYOSTED (AUTOINJECTOR) | testosterone enanthate | SOLUTION;SUBCUTANEOUS | 209863-001 | Sep 28, 2018 | RE44846 | ⤷ Subscribe |
Antares Pharma Inc | XYOSTED (AUTOINJECTOR) | testosterone enanthate | SOLUTION;SUBCUTANEOUS | 209863-002 | Sep 28, 2018 | RE44846 | ⤷ Subscribe |
Antares Pharma Inc | XYOSTED (AUTOINJECTOR) | testosterone enanthate | SOLUTION;SUBCUTANEOUS | 209863-001 | Sep 28, 2018 | RE44847 | ⤷ Subscribe |
Antares Pharma Inc | XYOSTED (AUTOINJECTOR) | testosterone enanthate | SOLUTION;SUBCUTANEOUS | 209863-003 | Sep 28, 2018 | RE44846 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for XYOSTED (AUTOINJECTOR)
See the table below for patents covering XYOSTED (AUTOINJECTOR) around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 2014525783 | ⤷ Subscribe | |
Japan | 6640907 | ⤷ Subscribe | |
South Korea | 101597672 | ⤷ Subscribe | |
South Korea | 20150011346 | NEEDLE ASSISTED JET INJECTION ADMINISTRATION OF TESTOSTERONE COMPOSITIONS | ⤷ Subscribe |
Japan | 2016104214 | 危険有害性薬剤の注入システム (INJECTION SYSTEM OF DANGEROUS AND ADVERSE AGENT) | ⤷ Subscribe |
Australia | 2010226442 | Hazardous agent injection system | ⤷ Subscribe |
>Country | >Patent Number | >Title | >Estimated Expiration |
XYOSTED (AUTOINJECTOR) Market Analysis and Financial Projection Experimental
More… ↓